Equities analysts forecast that CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will report earnings per share of ($0.07) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for CASI Pharmaceuticals’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.08). CASI Pharmaceuticals reported earnings per share of ($0.09) during the same quarter last year, which would suggest a positive year over year growth rate of 22.2%. The company is expected to issue its next quarterly earnings report on Monday, May 10th.
According to Zacks, analysts expect that CASI Pharmaceuticals will report full year earnings of ($0.24) per share for the current fiscal year, with EPS estimates ranging from ($0.35) to ($0.17). For the next year, analysts expect that the firm will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.38) to ($0.17). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow CASI Pharmaceuticals.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings results on Monday, March 29th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). CASI Pharmaceuticals had a negative return on equity of 60.96% and a negative net margin of 402.87%.
In other news, CEO Wei-Wu He bought 3,000,000 shares of the stock in a transaction on Friday, March 26th. The stock was acquired at an average price of $2.05 per share, with a total value of $6,150,000.00. Following the acquisition, the chief executive officer now directly owns 4,683,994 shares in the company, valued at $9,602,187.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 24.75% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of CASI. Marshall Wace LLP acquired a new position in CASI Pharmaceuticals in the 1st quarter worth about $44,000. BlackRock Inc. grew its position in shares of CASI Pharmaceuticals by 1.0% in the 3rd quarter. BlackRock Inc. now owns 3,511,724 shares of the biotechnology company’s stock valued at $5,373,000 after buying an additional 36,422 shares during the last quarter. State Street Corp grew its position in shares of CASI Pharmaceuticals by 6.5% in the 3rd quarter. State Street Corp now owns 1,017,612 shares of the biotechnology company’s stock valued at $1,557,000 after buying an additional 62,380 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of CASI Pharmaceuticals by 40.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 471,893 shares of the biotechnology company’s stock valued at $722,000 after buying an additional 137,097 shares during the last quarter. Finally, Consonance Capital Management LP bought a new stake in shares of CASI Pharmaceuticals in the 3rd quarter valued at about $10,037,000. 31.95% of the stock is owned by institutional investors and hedge funds.
Shares of CASI Pharmaceuticals stock traded down $0.03 during trading on Friday, reaching $2.02. 46,728 shares of the company’s stock were exchanged, compared to its average volume of 1,183,457. CASI Pharmaceuticals has a 1-year low of $1.46 and a 1-year high of $3.90. The firm’s 50-day moving average price is $2.37 and its 200 day moving average price is $2.45. The company has a market cap of $282.39 million, a P/E ratio of -4.56 and a beta of 0.41.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China.
Featured Article: Futures Contract
Get a free copy of the Zacks research report on CASI Pharmaceuticals (CASI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com